TCGA-86-7714-01A-12R-2170-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.250
- UV_RESPONSE_DN+0.240
- KRAS_SIGNALING_UP+0.210
- INTERFERON_ALPHA_RESPONSE+0.190
- NOTCH_SIGNALING+0.190
- PANCREAS_BETA_CELLS+0.190
- TGF_BETA_SIGNALING+0.180
- HEDGEHOG_SIGNALING+0.170
- ANDROGEN_RESPONSE+0.150
- BILE_ACID_METABOLISM+0.140
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- E2F_TARGETS-0.550
- MYC_TARGETS_V1-0.500
- G2M_CHECKPOINT-0.480
- MTORC1_SIGNALING-0.430
- OXIDATIVE_PHOSPHORYLATION-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.370
- DNA_REPAIR-0.290
- GLYCOLYSIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-7573-01A-11R-2039-07 | — | cohortA1 | 0.912 |
| 2 | TCGA-50-5942-01A-21R-1755-07 | — | cohortA1 | 0.890 |
| 3 | TCGA-GD-A3OP-01A-21R-A220-07 | — | — | 0.865 |
| 4 | 5c61f3fb-d3c5-4628-89a8-94bd513e8fa4 | — | — | 0.864 |
| 5 | C3L-03268 | — | cohortA1 | 0.857 |
| 6 | TCGA-44-6147-01A-11R-1755-07 | — | cohortA1 | 0.854 |
| 7 | BS_2SFTWNVE | Med | Medulloblastoma | 0.853 |
| 8 | TCGA-44-5645-01A-01R-1628-07 | — | cohortA1 | 0.843 |
| 9 | TCGA-55-8206-01A-11R-2241-07 | — | cohortA1 | 0.843 |
| 10 | C3N-03038 | — | cohortA1 | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.060 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.050 | Inavolisib | — uncovered |